1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Capital Allocation
INVESTOR
Life science toolmakers that enable drug production operate attractive businesses for two major reasons that investors often find compelling. First, regulation of the drug manufacturing process creates highly durable switching costs for end users and long potential revenue streams for life science toolmakers. Second, life science firms often benefit from broad exposure to biopharmaceutical growth without taking on much product-specific risk.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2022, Waters generated 59% from pharmaceutical customers, 31% from industrial clients, and 10% from academic/government institutions.
Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of WAT’s competitive advantage.
Waters Corp
XNYS: WAT
| Agilent Technologies Inc
XNYS: A
| Danaher Corp
XNYS: DHR
| Thermo Fisher Scientific Inc
XNYS: TMO
| |
Price
| 249.28 | 115.79 | 235.37 | 518.18 |
Currency
| USD | USD | USD | USD |
Change
| −$0.68 (0.27%) | +$1.10 (0.96%) | −$0.04 (0.02%) | +$2.93 (0.57%) |
Market Cap
| 14.72 Bil | 34.20 Bil | 173.68 Bil | 199.87 Bil |
Industry
| Diagnostics & Research | Diagnostics & Research | Diagnostics & Research | Diagnostics & Research |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
No. WAT does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
WAT’s market cap is 14.72 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
WAT’s stock style is Mid Core.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
WAT’s price/sales is 5.04.
Price/sales represents the amount an investor is willing to pay for a dollar generated from
a particular company’s sales or revenues.
WAT’s price/forward earnings is 21.70.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates.
The lower the Forward P/E, the cheaper the stock.
WAT’s price/book is 24.53.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets,
based on historical, rather than current, valuations. Historical valuations generally do not reflect
a company’s current market value. Value investors frequently look for companies that have low price/book ratios.
See WAT’s valuation ratios compared to the Market Index.
WAT’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare WAT’s historical performance against its industry peers and the overall market.
